@article{c9c10e3fc5c34b42a4603f8463e8f4e2,
title = "Acceptability of randomization to levonorgestrel versus copper intrauterine device among women requesting IUD insertion for contraception",
abstract = "Objective Assess feasibility of randomizing women to intrauterine device (IUD) type. Study Design Women enrolling in a 2-month study who desired an IUD for contraception were randomized 1:1 to receive a levonorgestrel-releasing 52-mg IUD (LNG-IUD) or copper T380A IUD (Cu-IUD), understanding they could switch IUD type at the end of the study. Results Randomization to IUD type was acceptable to 54/55 (98%) women who screened. All 32 enrolled participants completed follow-up. Two women exchanged their IUD (Cu-IUD to LNG-IUD), and two requested removal (one LNG-IUD, one Cu-IUD). Overall, 88% continued their assigned IUD. Conclusions Randomization to IUD type is feasible, and few women change their IUD.",
keywords = "Contraception, IUD randomization, Intrauterine device, Randomization",
author = "Achilles, {Sharon L.} and Chen, {Beatrice A.} and Lee, {Jessica K.} and Gariepy, {Aileen M.} and Creinin, {Mitchell D.}",
note = "Funding Information: The authors would like to thank Jennefer Russo, Heather Hohmann and the staff of the Center for Family Planning Research for their assistance with this research. This research was supported by an anonymous foundation, The Bill & Melinda Gates Foundation and US National Institutes of Health/National Institute of Allergy and Infectious Diseases (NIH R01-AI102835 ). The funding sources had no role in study conduct, article preparation or the decision to submit the article for publication. The findings reported herein were presented in part at the North American Forum on Family Planning in Denver, CO, October, 2012. Funding Information: Conflicts of interest: Dr. Creinin is a consultant for Merck, Actavis, Bayer, Danco, Teva and Polkadoc. The Department of Obstetrics and Gynecology at the University of California, Davis, receives funding for contraceptive research from Merck and Medicines360 . The Department of Obstetrics, Gynecology and Reproductive Sciences at the University of Pittsburgh receives research funding from Medicines360 , Bayer and Agile Therapeutics . The remaining authors report no conflicts of interest. Publisher Copyright: {\textcopyright} 2015 Elsevier Inc.",
year = "2015",
month = dec,
day = "1",
doi = "10.1016/j.contraception.2015.08.009",
language = "English (US)",
volume = "92",
pages = "572--574",
journal = "Contraception",
issn = "0010-7824",
publisher = "Elsevier USA",
number = "6",
}